- The shares of Eli Lilly And Co (NYSE: LLY) have received a price target increase from $227 to $250 from Barclays. These are the details.
The shares of Eli Lilly And Co (NYSE: LLY) have received a price target increase from $227 to $250 from Barclays. And Barclays analyst Carter Gould is maintaining an “Overweight” rating on the company shares.
Gould had increased the probability of success for donanemab to 60% from 30%. And Gould also cited that the company made modest pipeline changes.
Eli Lilly recently announced that it is planning to file for FDA approval of donanemab for Alzheimer’s disease later this year under an accelerated approval pathway. Truist analyst Gregg Gilbert recently pushed forward his expectation of approval by 2 years to 2023 and boosted his probability of success to 90% from 75%.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.